[ad_1]
Pfizer and BioNTech are planning to launch clinical trials of their Covid-19 vaccine targeting Delta next month, fearing that the existing jabs will not prevent complications that could spread rapidly around the world.
Manufacturers of the drug are developing a new type of vaccine that can be made using Delta varieties, Pfizer said Thursday. Pfizer and BioNTech are in talks with U.S. medical regulators to finalize medical plans and hope to begin training in August.
The companies are the first to develop a vaccine that focuses on the Delta, suggesting that potential concerns could be overcome by existing jabs and new approaches will help.
The Delta virus was first discovered in India in December and has since spread to Europe and the US, leading to the spread of the coronavirus, especially among people who have not been vaccinated. Delta is now severe stress in the US, according to the Centers for Disease Control and Prevention, I account for more than 90 percent of new Covid cases in the UK.
Pfizer reiterated its belief that a third of its vaccine should be given six to 12 months after the second dose of its two vaccines will be required to protect new species.
It also said it would soon publish more confirmations of the third shot, and plans to report to the U.S. Food and Drug Administration “in the coming weeks”.
The New York-based company described earlier reports published last month that showed two doses of vaccine that made the drug resistant to Delta, but said the effectiveness of the vaccine was shown to be less than six months after vaccination.
Recent cases of coronavirus
Follow FT’s description and report on the global epidemic and the rapidly changing economic crisis Pano.
“Although we believe that the third part of [our vaccine] has the potential to maintain adequate protection against all known species here including Delta, we remain vigilant and develop a new type of Pfizer-Covid-19 vaccine, “says Pfizer.
An investigation by the Israeli Ministry of Health this week showed that BioNTech / Pfizer jab was 93% effective in preventing serious and clinical illnesses from the Delta, but only 64% effective in preventing infection from a variety of sources.
Moderna and Johnson & Johnson have both said that preliminary data show their jabs release antibodies against Delta.
[ad_2]
Source link
